Oculis (OCS) News Today → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free OCS Stock Alerts $12.02 +0.07 (+0.59%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineOculis shares target cut, retains buy rating on completed equity financinginvesting.com - April 26 at 5:05 PMOptimistic Buy Rating for Oculis Holding Ahead of Key OCS-02 Drug Data Releasemarkets.businessinsider.com - April 26 at 12:04 PMOculis Holding AG to Post Q2 2024 Earnings of ($0.37) Per Share, HC Wainwright Forecasts (NASDAQ:OCS)marketbeat.com - April 26 at 8:23 AMabrdn plc Acquires Shares of 1,452,741 Oculis Holding AG (NASDAQ:OCS)marketbeat.com - April 25 at 6:15 AMAnalysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Day One Biopharmaceuticals (DAWN)markets.businessinsider.com - April 24 at 2:26 PMOculis (NASDAQ:OCS) Price Target Lowered to $28.00 at HC Wainwrightmarketbeat.com - April 24 at 8:35 AMOculis Holding AG: Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Marketfinanznachrichten.de - April 22 at 12:41 PMOculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Marketglobenewswire.com - April 22 at 9:27 AMOculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Marketglobenewswire.com - April 22 at 8:34 AMShort Interest in Oculis Holding AG (NASDAQ:OCS) Declines By 31.4%marketbeat.com - April 12 at 9:38 PMOculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Marketglobenewswire.com - April 11 at 8:55 AMOculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Developmentglobenewswire.com - April 10 at 6:30 AMOculis Holding AG (NASDAQ:OCS) Given Average Recommendation of "Buy" by Brokeragesmarketbeat.com - April 9 at 4:26 AMPositive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meetingglobenewswire.com - April 8 at 6:30 AMOculis to Participate at Upcoming April Investor Conferencesglobenewswire.com - April 4 at 6:30 AMOculis Holding (NASDAQ:OCS): Riding on Bullish Expectationsmsn.com - March 25 at 6:49 PMLeerink Partnrs Comments on Oculis Holding AG's Q1 2024 Earnings (NASDAQ:OCS)marketbeat.com - March 22 at 7:35 AMBuy Rating Affirmed on Oculis Holding with Promising Clinical Pipeline and Strong Financial Positionmarkets.businessinsider.com - March 19 at 6:37 PMOculis (NASDAQ:OCS) Stock Rating Reaffirmed by Chardan Capitalmarketbeat.com - March 19 at 9:33 AMOculis (NASDAQ:OCS) PT Lowered to $35.00 at Robert W. Bairdmarketbeat.com - March 19 at 8:20 AMOculis Holding AG: Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progressfinanznachrichten.de - March 18 at 11:24 AMOculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progressglobenewswire.com - March 18 at 6:30 AMOculis Holding AG (NASDAQ:OCS) Given Average Rating of "Buy" by Analystsmarketbeat.com - March 15 at 6:42 AMBuy Rating Affirmed: Oculis Holding’s Promising Ophthalmic Therapies Poised for Market Impactmarkets.businessinsider.com - March 6 at 4:49 PMOculis Holding AG (NASDAQ:OCS) Sees Large Drop in Short Interestmarketbeat.com - March 1 at 10:37 AMAnalysts Are Bullish on Top Healthcare Stocks: Jazz Pharmaceuticals (JAZZ), Oculis Holding (OCS)markets.businessinsider.com - March 1 at 7:03 AMBuy Rating Affirmed for Oculis Holding on Promising DME and DED Drug Prospectsmarkets.businessinsider.com - March 1 at 7:03 AMBuy Rating Reaffirmed for Oculis Holding Amid Promising Clinical Trials and Market Potentialmarkets.businessinsider.com - February 29 at 4:03 PMOculis (NASDAQ:OCS) Given Buy Rating at HC Wainwrightmarketbeat.com - February 29 at 9:29 AMOculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointmentsglobenewswire.com - February 28 at 6:30 AMNan Fung Group Holdings Ltd Reduces Stake in Oculis Holding AG (NASDAQ:OCS)marketbeat.com - February 25 at 10:37 AMOculis Holding AG (NASDAQ:OCS) Given Average Rating of "Buy" by Brokeragesmarketbeat.com - February 19 at 5:40 AMOculis (NASDAQ:OCS) Stock Price Up 0.4%marketbeat.com - February 17 at 3:11 AMHow Much Upside is Left in Oculis Holding AG (OCS)? Wall Street Analysts Think 152.77%finance.yahoo.com - February 1 at 12:43 PMWhat Makes Oculis Holding AG (OCS) a Good Fit for 'Trend Investing'finance.yahoo.com - January 29 at 3:55 PMOculis to Present at Upcoming February Investor Conferencesfinance.yahoo.com - January 29 at 9:45 AMOculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024finance.yahoo.com - January 22 at 9:16 AMCan Oculis Holding AG (OCS) Climb 191.31% to Reach the Level Wall Street Analysts Expect?finance.yahoo.com - January 16 at 4:08 PMOculis Holding AG (NASDAQ:OCS) Given Consensus Recommendation of "Buy" by Brokeragesmarketbeat.com - December 31 at 6:34 AMOptimistic Buy Rating for Oculis Holding on OCS-01 Progress and Market Potentialmarkets.businessinsider.com - December 21 at 8:13 PMOculis Holding Stock (NASDAQ:OCS), Analyst Ratings, Price Targets, Predictionsbenzinga.com - December 20 at 10:21 PMOculis Holding Stock (NASDAQ:OCS) Earnings Dates and Earning Callsbenzinga.com - December 20 at 5:21 PMOculis Holding AG: Oculis Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edemafinanznachrichten.de - December 20 at 12:20 PMOculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgeryfinance.yahoo.com - December 20 at 7:20 AMOculis Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edemafinance.yahoo.com - December 18 at 8:23 AMOculis Holding AG (NASDAQ:OCS) Short Interest Down 18.8% in Novembermarketbeat.com - December 15 at 9:36 PMOculis Holding’s Promising Clinical Progress Justifies Buy Ratingmarkets.businessinsider.com - December 11 at 7:31 PMOculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNFa Licaminlimab (OCS-02) in Dry Eye Diseasetmcnet.com - December 7 at 9:33 AMOculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Diseasefinance.yahoo.com - December 7 at 9:33 AMChardan Capital Initiates Coverage of Oculis Holding (OCS) with Buy Recommendationmsn.com - December 5 at 7:13 PM Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Email Address The Next Step of Their Control Is Here … (Ad)Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you. 4 simple steps to protect your privacy and money before it’s too late. OCS Media Mentions By Week OCS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCS News Sentiment▼0.380.32▲Average Medical News Sentiment OCS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCS Articles This Week▼122▲OCS Articles Average Week Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KALV News Today TBPH News Today TVTX News Today SLRN News Today LRMR News Today ANNX News Today FULC News Today CDMO News Today MRSN News Today NGNE News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCS) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
